Stock TAPIMMUNE INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. TapImmune Inc. Other OTC

Equities

US8760333091

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for TapImmune Inc.
Mar. 27 North American Morning Briefing : Stocks Edge -2- DJ
Mar. 25 Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Piper Sandler Adjusts Marker Therapeutics' Price Target to $1.50 From $3.50, Reiterates Overweight Rating
MT
Oppenheimer Adjusts Marker Therapeutics' Price Target to $5 From $8, Maintains Outperform Rating
MT
Roth Capital Downgrades Marker Therapeutics to Neutral From Buy, Adjusts Price Target to $1 From $3
MT
MARKER THERAPEUTICS : Piper Sandler Starts Marker Therapeutics at Overweight with $6 Price Target
MT
MARKER THERAPEUTICS : Cantor Fitzgerald Initiates Marker Therapeutics at Overweight Rating With $6 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRKR Stock
  4. Stock
  5. News TapImmune Inc.
  6. Analyst Reco.